{"entity":{"id":"3d-medicines","kind":"company","name":"3D Medicines","aka":["3D Medicines (Sichuan) Co., Ltd.","3D Medicines Inc.","思路迪"],"tldr":"3D Medicines is a Chinese biotechnology company that co-developed envafolimab, the first subcutaneous PD-L1 antibody, approved in China in 2021 for microsatellite instability-high solid tumours.","summary":"3D Medicines, headquartered in Sichuan with research in Shanghai and listed in Hong Kong since 2022, develops immuno-oncology antibodies. With Alphamab Oncology and Tracon it brought envafolimab (KN035), a single-domain PD-L1 antibody given by subcutaneous injection, to approval in China in November 2021 for previously treated MSI-high or dMMR advanced solid tumours, and it runs phase 3 trials of the drug in combination with chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by 3D Medicines","url":"https://clinicaltrials.gov/search?lead=3D%20Medicines"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":["pdl1"],"drugs":["envafolimab"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06123754","nct04891198","nct03667170","nct05024214","nct03478488","nct05112991"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.3d-medicines.com","stage":"public","investors":[],"funding":[]},"route":"/companies/3d-medicines/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}],"trial":[{"id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/"},{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","route":"/trials/nct03667170/"},{"id":"nct04910386","kind":"trial","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","route":"/trials/nct04910386/"},{"id":"nct05024214","kind":"trial","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","route":"/trials/nct05024214/"},{"id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/"},{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/"},{"id":"nct05112991","kind":"trial","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","route":"/trials/nct05112991/"}]}}